mRNA |
parbendazole |
CTRPv2 |
pan-cancer |
AAC |
-0.062 |
0.05 |
mRNA |
prima-1 |
CTRPv2 |
pan-cancer |
AAC |
0.063 |
0.05 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.067 |
0.05 |
mRNA |
Merck60 |
CTRPv2 |
pan-cancer |
AAC |
-0.06 |
0.05 |
mRNA |
BRD-K64610608 |
CTRPv2 |
pan-cancer |
AAC |
0.077 |
0.05 |
mRNA |
nelarabine |
CTRPv2 |
pan-cancer |
AAC |
0.076 |
0.05 |
mRNA |
ML050 |
CTRPv2 |
pan-cancer |
AAC |
0.074 |
0.05 |
mRNA |
BRD9876:MK-1775 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.24 |
0.05 |
mRNA |
AZD1480 |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.06 |
mRNA |
LRRK2-IN-1 |
CTRPv2 |
pan-cancer |
AAC |
0.072 |
0.06 |